First-in-class antibody mixture shows clinical activity against Tx-resistant, advanced colorectal cancer
Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic ...